Skip to main content

Table 2 HIV-1 subtype and drug resistance mutations in patients

From: Short-term treatment outcomes in human immunodeficiency virus type-1 and hepatitis B virus co-infections

Cases

Controls

KAF

Subtype

Mutationsa

GSSa

HIV-1 VL

KAF

Subtype

Mutationsa

GSSa

HIV-1 VL

151

CRF02_AG

0

5.38

075

CRF02_AG

0

5.08

083

CRF02_AG

0

5.74

124

CRF02_AG

0

5.46

092

CRF02_AG

0

5.87

023

CRF01_AE

na

na

5.49

028

CRF02_AG

0

5.26

130

CRF02_AG/G

0

5.73

090

G

0

4.76

033

A/CRF01_AE

V118I

0

6.02

056

G

na

na

5.33

081

CRF02_AG

0

5.39

071

CRF02_AG

V108I, V179E

25

5.16

078

CRF02_AG

E138A

0

3.52

120

CRF02_AG

0

5.65

104

G

V108I

15

5.18

026

CRF02_AG

0

5.76

149

CRF02_AG

0

4.65

115

CRF02_AG

0

5.09

074

CRF02_AG

0

5.73

031

CRF02_AG

V90I

0

4.87

137

A/CRF02_AG

0

5.28

061

CRF02_AG

0

5.86

010

CRF02_AG

0

6.33

077

CRF02_AG

0

5.52

064

na

na

na

6.45

041

G

V108IV, E138A, V179EV

10

4.20

121

CRF02_AG

0

6.27

156

CRF02_AG

0

5.54

037

CRF02_AG

0

5.49

011

CRF02_AG

V90I

0

5.31

095

CRF02_AG

0

6.15

109

CRF02_AG

0

6.08

019

G

0

6.16

200

na

na

na

na

024

CRF02_AG

0

4.46

  1. KAF, patients ID; Cases, individuals infected with HIV and HBV; Controls, those infected with only HIV; Mutationsa/GSSa, HIV-1 drug resistance mutations/genotypic sensitivity scores (GSS) based on specific ARVs used by patients as determined by the Stanford database (analyzed on July 8, 2014); HIV-1 VL, pre-HAART HIV-1 plasma viral load. Subtypes were determined by the Stanford database
  2. na not available